Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: BMS buys Mirati; slow Q3 for biopharma M&A; Roche on its neuroscience strategy; Alexion talks about AstraZeneca integration; and Gilead on trial diversity.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 13 October 2023, including: Bristol Myers Squibb Company buys Mirati Therapeutics, Inc.; slow Q3 for biopharma M&A; Roche Holding AG on its neuroscience strategy; Alexion Pharmaceuticals Inc. talks about AstraZeneca PLC integration; and Gilead Sciences, Inc. on trial diversity.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "BMS Looks To Expand Its Oncology Reach With Mirati Buyout" - Scrip, 9 Oct, 2023.)
(Also see "Slow Q3 For Biopharma M&A Boosted By Biogen/Reata" - Scrip, 10 Oct, 2023.)
(Also see "Already Number One In Neuroscience, Roche Extends Ionis RNA Partnership To Tackle Alzheimer’s And Huntington’s" - Scrip, 11 Oct, 2023.)
(Also see "Alexion On Its AstraZeneca Integration And Growth Plan" - Scrip, 10 Oct, 2023.)
(Also see "How Gilead Did Trial Diversity Before It Was Cool" - Scrip, 6 Oct, 2023.)